- Track your favorite companies
- Receive email alerts for new filings
- Personalized dashboard of news and more
- Access all data and search results
Content analysis
?Positive | ||
Negative | ||
Uncertain | ||
Constraining | ||
Legalese | ||
Litigous | ||
Readability |
H.S. sophomore Avg
|
- 10-K Annual report
- 10.20 Exhibit 10.20
- 10.21 Exhibit 10.21
- 10.22 Exhibit 10.22
- 10.23 Exhibit 10.23
- 10.24 Exhibit 10.24
- 10.25 Exhibit 10.25
- 10.26 Exhibit 10.26
- 21 Exhibit 21
- 23.1 Exhibit 23.1
- 23.2 Exhibit 23.2
- 31.1 Exhibit 31.1
- 31.2 Exhibit 31.2
- 32.1 Exhibit 32.1
- 32.2 Exhibit 32.2
- Download Excel data file
- View Excel data file
Exhibit 23.2
Consent of Independent Registered Public Accounting Firm
We consent to the incorporation by reference in the Registration Statements ofCASI Pharmaceuticals, Inc.on Forms S-8 (File Nos. 333-101617, 333-222043 and 333-228980) and Forms S-3 (File Nos.333-80193, 333-84907, 333-76824, 333-104380, 333-110604, 333-122309, 333-133190, 333-132715, 333-151542, 333-167754, 333-182803, 333-200927, 333-214889, 333-222046, 333-222701, 333-228383 and 333-226206) of our report,dated March 29, 2018 onour audit of the consolidated financial statements ofCASI Pharmaceuticals, Inc., as of December 31, 2017 and for the year then ended, included in this Annual Report on Form 10-K of CASI Pharmaceuticals, Inc. for the year ended December 31, 2018.
/s/CohnReznick LLP |
Roseland, New Jersey
March 29, 2019